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Following the discovery of its potent antitumoral activity in
1965, the inorganic drug cisplatin has become one of the most
important anticancer agents in clinical use.[1] It exhibits
exceptional activity against germ-cell testicular cancer, for
which it is the first-line therapeutic option.[2] Its success led to
the development of second-generation drugs, namely carbo-
platin and oxaliplatin, both of which are also based on the cis-
diam(m)ineplatinum(II) pharmacophore. Together, these
FDA-approved PtII drugs constitute some of the most
widely used chemotherapeutic agents (Figure 1).[3] Yet,
despite their clinical success, the use of PtII drugs is limited
by their high toxicity, severe side-effects, and incidences of
drug resistance.[4] To address some of these limitations,
researchers have developed stable PtIV carboxylate com-
plexes as anticancer prodrugs that can be activated by
intracellular reduction to release their latent cytotoxic
activity.[5] This versatile strategy has been used to develop
PtIV prodrug complexes with highly tuned properties,[6] which
are capable of targeting,[7] as well as delivering novel modes of
action.[8] The most prominent example is satraplatin, which is
currently undergoing Phase III clinical trials against hor-
mone-refractory prostate cancer (Figure 1).[9] Although there
is much interest in understanding and exploiting this prodrug
strategy as a springboard towards the next generation of
Pt drugs, tools capable of directly visualizing the uptake and
accumulation of these clinically important compounds are
lacking. Herein, we describe a fluorescent probe that was
custom-built for the detection of PtII drugs such as cisplatin.
Using confocal microscopy, we could determine the local-
ization of the PtIV prodrugs in cancer cells in vitro after cell
entry and intracellular reduction.
Elucidating how PtIV prodrugs are processed after cell
entry would significantly improve our understanding of these
compounds. Hambley et al. used elemental tomography to
map the uptake of PtIV prodrug complexes by tumor
spheroids. Using X-ray near edge adsorption spectroscopy
(XANES), they showed that cancer cells treated with PtIV
prodrugs contained both PtIV and PtII species.[10] However,
these techniques required synchrotron X-ray radiation, and so
cannot be applied to living cells. Elemental-analysis tech-
niques, such as graphite-furnace atomic-absorption spectrom-
etry (GF-AAS) and inductively coupled plasma mass spec-
trometry (ICP-MS), have also been used extensively to
quantitate the Pt distribution in tissue or cellular compart-
ments, but they cannot be applied in cellular imaging.[11] More
recently, NanoSIMS was used to map the accumulation of
cisplatin and the multinuclear Pt drug candidate TriplatinNC
in vitro, but it cannot distinguish between different Pt
oxidation states (NanoSIMS= nanoscale secondary ion
mass spectrometry).[12]
Fluorescence microscopy remains the most effective and
accessible method for imaging at the cellular level. Using
immunofluorescence, Lippard and co-workers demonstrated
that, after administration, PtIV prodrugs were capable of
forming nuclear Pt–DNA adducts in vitro, which were their
biological target.[13] To visualize the reduction process,
fluorophores have also been attached directly to the PtIV
scaffold, resulting in fluorescence quenching of its PtII
congener.[14] Reduction was accompanied by a concomitant
enhancement in fluorescence intensity, which, in principle,
provides the most direct method for visualizing reduction. Pt
complexes have also been labeled, either directly or through
the use of post-labeling strategies, with fluorophores to study
their intracellular distribution.[15] However, modification of
the PtIV complexes with such bulky organic groups changes
the pharmacophore and alters their uptake characteristics,
thus rendering them different from cisplatin.
Therefore, an ideal imaging probe should be delinked
from the Pt scaffold and yet be selective enough to distinguish
between PtIV/PtII within a complex cellular environment.
Koide and Garner developed a fluorescein-based chemo-
dosimeter that detects Pt through Tsuji–Trost allylic bond
cleavage.[16] The system required prior conversion of the Pt
Figure 1. FDA-approved PtII drugs and a PtIV prodrug evaluated in
clinical trials.
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species into Pt0, but was capable of detecting cisplatin with
high specificity in a range of buffer conditions. Using
combinatorial library synthesis, Tae et al. also disclosed
a rhodamine–triazole probe that is capable of detecting PtII
species such as cisplatin through the ring opening of its
spirolactam motif.[17]
We reasoned that it would be possible to engineer
a fluorescent probe specifically designed for the detection of
PtII drugs in a cellular environment by taking advantage of the
difference in reactivity between the PtIV prodrug and its PtII
congener. As PtIV prodrug complexes are kinetically inert
because of their saturated coordination sphere and stable
electronic configuration, we could design functional groups
that would selectively interact with PtII species. Examples of
such functional groups include dithiocarbamates and dithio-
carbamate esters.[18] Indeed, in clinical trials, sodium dieth-
yldithiocarbamate (NaDDTC) was found to sequester excess
administered cisplatin, and to mitigate systemic toxicity
induced by the therapy.[19] Our strategy was to tether the
non-fluorescent spirolactam form of rhodamine B (RhoB) to
a recognition motif comprised of DDTC (Supporting Infor-
mation, Scheme S1). The recognition motif would bind PtII
species through the dithiocarbonyl bond; thereby, the trans
ligands are labilized for reactions with the spirolactam motif,
and the fluorescence is selectively turned on.[20]
The target probe Rho-DDTC was prepared in three steps
(Scheme S1). RhoB was treated sequentially with POCl3 and
NH2OH to obtain hydroxamate derivative 1. Reaction with
excess 1,2-dibromoethane in the presence of triethylamine as
a base yielded 2, which was quantitatively converted into
Rho-DDTC by a reaction with NaDDTC. The C2 spacer
between the Rho and DDTC motifs was employed to
facilitate positioning of bound Pt at the spirolactam upon
DDTC-binding. Rho-DDTC was fully characterized by 1H
and 13C NMR, ESI-MS, and single-crystal X-ray crystallo-
graphic analyses (see the Supporting Information). The spiro
form was confirmed in solution by the presence of the
13C resonance of the spiro C atom at ca. 65 ppm (CDCl3 and
[D6]DMSO), as well as in the solid state (Figure 2, C8). The
crystal structure shows that the thiocarbonyl group is oriented
towards the spirolactam, presumably to minimize steric
repulsion between the NEt2 substituent of the carbamate
and the xanthine ring, thus affording a suitable binding
configuration.
Detection of Pt2+ using Rho-DDTC was investigated in
HEPES buffer (20 mm, pH 7.4, 30% EtOH). The probe was
stable over a large pH range (3.5–12) and hence compatible
with physiological conditions (Figure S4). When K2PtCl4 was
added as the Pt2+ source (80 mm), a visible change from
colorless to pink was observed after 5 min with a 60-fold
increase in absorbance at lmax= 565 nm, as observed by UV/
Vis spectroscopy (Figure S5). A strong fluorescence turn-on
response was also recorded at lem= 584 nm (lex= 490 nm)
with a 65-fold enhancement relative to the control. At Pt2+
concentrations between 10–80 mm, both absorbance and
fluorescence increased linearly (Figure S6). Analysis of
a Jobs plot indicated maximum fluorescence intensity at
a mole fraction of 0.5, which suggests that Rho-DDTC
interacted with Pt2+ in a 1:1 ratio (Figure S7). The selectivity
of Pt2+ was high, as the use of other metal ions, such as Na+,
K+, Mg2+, Cu2+, Ni2+, Zn2+, Fe2+, and Fe3+, which play
important roles in biological systems, only led to baseline
values in the emission and absorption spectra (Figure S8).
Compared to Pt2+, the detection of cisplatin was slower under
similar reaction conditions and required at least 60 min before
a fluorescence signal could be measured. The selectivity for
cisplatin compared to other metal ions remained high, even at
elevated concentrations (Na, K, and Mg at ca. 15 mm), which
is essential for its application as an intracellular probe
(Figure S9).
To fully exploit Rho-DDTC as a probe for Pt drugs, we
sought to understand its underlying mechanism of action. We
postulated that aquation was essential for probe activation,
because cisplatin readily undergoes aquation to form reactive
aqua species. However, even after aquation was suppressed
with 1m NaCl, the probe could still be activated, which thus
suggests alternate pathways. Hence, we evaluated Rho-
DDTC against several cis-[PtA2X2] scaffolds (A=
am(m)ine) to understand the role of the ligands in probe
activation (Table S2). Intriguingly, when chelating A ligands
were present, the PtII complex could not activate the probe.
To understand this observation, the reaction products of
K2PtCl4, cisplatin, carboplatin, and JM118 with Rho-DDTC
were analyzed by ESI-MS. The mass shifts indicated retention
of an ammine and a cyclohexylamine ligand on the Rho-
DDTC/cisplatin and Rho-DDTC/JM118 adducts, respec-
tively (Figure S10). JM118 exclusively formed adducts con-
taining the cyclohexylamine ligand (m/z 1057), whereas
adducts with the alternate ammine ligand (m/z 976) were
absent. Furthermore, the same adducts were formed from
cisplatin and carboplatin, which indicates that CBDCA was
displaced.
Taken together, the data suggested that the displacement
of an am(m)ine ligand is a critical step for Rho-DDTC
activation. We reasoned that, in the absence of aquation, PtII
complexes first bind to a reactive DDTC motif with
concomitant displacement of an ammine ligand (Scheme S2).
Figure 2. Molecular representation of Rho-DDTC; ellipsoids set at
50% probability.
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The incident thiocarbonyl group labilizes X because of the
trans effect; this induces nucleophilic attack on Pt by the
spirolactam motif and activates the probe. As initial binding
of JM118 would be affected by steric hindrance from cyclo-
hexylamine, we expect the ammine ligand to be displaced.
Furthermore, the chelating ethylenediamine (en) ligand
confers kinetic stability to cis-[Pt(en)Cl2], making displace-
ment of the amine ligand unfavorable. Indeed, for oxaliplatin,
probe activation was not observed, presumably because of its
stable DACH chelate.
We therefore investigated the ability of Rho-DDTC to
distinguish between PtII drugs and their parental PtIV com-
plexes. In contrast to cisplatin, PtIV complexes 3–6, which are
based on the cisplatin template, did not trigger fluorescence
turn-on (Figure 3). The reduction of PtIV prodrug complexes
is highly dependent on the nature of their axial ligands.
Previous structure-activity relationship (SAR) studies have
shown that complexes with axial chloride ligands are most
readily reduced, followed by carboxylates, with hydroxo
ligands being most resistant.[5a,21] Rho-DDTC was robust
enough to distinguish 4 from cisplatin. Similarly, Rho-DDTC
could distinguish JM118 from satraplatin, both of which
contain the asymmetric am(m)ine pharmacophore, thereby
providing a direct way of investigating this clinically impor-
tant drug candidate in biological systems.
We exposed HeLa cells to varying concentrations of
cisplatin, from 0.5 to 10 times its IC50 value (3 mm) for 3 h to
establish the sensitivity of the probe. Treated live cells were
incubated with Rho-DDTC, fixed with 4% paraformalde-
hyde, stained with Hoechst 33342 nuclear dye, and imaged
under a confocal fluorescence microscope. Internalization of
cisplatin was observed between two and ten times its IC50
value (Figure S11) and dispersed throughout the cytoplasm.
We noted that the fluorescence did not co-localize with the
nucleus stain because Rho-DDTC was unable to penetrate
the nuclear compartment. We therefore applied our fluores-
cence detection system to image PtII complexes (30 mm) in
HeLa cells to validate the observations. Intracellular fluores-
cence turn-on was achieved for cisplatin and JM118, which is
consistent with the earlier selectivity tests (Figure 3; see also
Figure S12). Oxaliplatin, which did not activate Rho-DDTC
in buffer solution, was not observed in treated cells under
these conditions (Figure S12). These tests demonstrated that
the detection of cis-[PtA2X2] scaffolds by Rho-DDTC did not
arise from non-specific interactions within the complex
cellular environment.
The current understanding entails that anticancer PtIV
prodrugs are themselves inactive and require chemical
reduction to cytotoxic PtII species, although this has never
been directly observed in live cells.[22] This evidence was
partially provided by a XANES study on frozen pellets of
A2780 ovarian cancer cells that had been treated with PtIV
prodrug complexes at high concentrations (200 mm), which
quantitated a high proportion of PtII species relative to PtIV
after 2 h of exposure.[10b,23] We speculated that this rapid
reduction occurs after cell entry within the cytoplasm.
Complexes 3 and 6 were selected as representative PtIV
prodrug complexes at opposite ends of the activity spectrum.
Complex 6 is hydrophobic (logP= 1.01), whereas 3 is highly
hydrophilic (logP=2.81). Although both complexes are
stable in culture media for 72 h, 3 resisted reduction by virtue
of its high reduction potential.[6d,23]
Cells treated with 3 and 6 (30 mm) exhibited fluorescence
after 3 h of treatment, indicating fast conversion into PtII
species (Figure 4). Fluorescence in cells treated with 3 was
Figure 3. Fluorescence profile of Rho-DDTC (lex=490 nm) after treat-
ment with PtII and PtIV complexes in HEPES buffer.
Figure 4. Merged fluorescence images of HeLa cells. a) Untreated
(control), and exposed to b) cisplatin, c) 3, and d) 6 (30 mm) for 3 h
and further incubated with Rho-DDTC (30 mm) for 1 h at 37 8C.
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well-dispersed within the cytoplasm, which is in line with the
results obtained for cisplatin, but at lower levels. In contrast,
the fluorescence profile observed for cells treated with 6 was
more intense and concentrated around the outer nuclear
envelope. This was presumably due to the highly hydrophobic
nature of 6, which results in its accumulation at the nuclear
lipid bilayer and is the subject of ongoing investigations. The
strong fluorescence profile of cells treated with 6 instead of 3
indicated greater availability of the cytotoxic PtII species in
the intracellular region, and can account for the significant
difference in cytotoxicity, with 6 more than 50 times more
efficacious than 3.[6d] The probe was further validated against
satraplatin and its PtII metabolite, JM118. Satraplatin is more
lipophilic than JM118 by virtue of two axial acetate ligands,
which also improve its oral bioavailability.[24] In line with the
results obtained for other PtIV carboxylates, cells treated with
satraplatin exhibited a high intracellular fluorescence
response, comparable to that obtained for JM118-treated
cells (Figure S12). However, we noted that the orally
administered satraplatin is only moderately stable in blood,
and can be reduced to JM118 in vivo prior to cellular
uptake.[25] This probe could still be useful in addressing
questions related to the circulation of satraplatin and its
distribution to distal organ/tumor sites after oral administra-
tion.
In conclusion, we have developed a fluorescent turn-on
probe rationally designed for the study of anticancer Pt
complexes within live cells. The probe is compatible with
biological conditions and designed to specifically target PtII
complexes containing the diam(m)ineplatinum(II) pharma-
cophore, including cisplatin. We found that the displacement
of an amine ligand is a prerequisite for the activation of the
fluorescence probe, and validated its selectivity between PtII
complexes with chelating and non-chelating amine ligands.
The probe is also able to distinguish between PtIV prodrug
complexes and their PtII products. For several PtIV prodrugs,
including satraplatin, we showed that reduction occurred
after cell entry and that the PtII products accumulated within
the cytoplasm. In summary, Rho-DDTC is a versatile tool for
the study of the localization of clinically important PtII
anticancer drugs and the activation of their PtIV prodrug
congeners within live cells.
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